Gallid herpesvirus 3 (ATCC® VR-2002)

Classification: Herpesviridae, Mardivirus  /  Product Format: frozen

Classification Herpesviridae, Mardivirus
Deposited As Marek's disease virus type 2
Agent Gallid herpesvirus 3
Strain SB
Applications
NOTE: This material is cited in a U.S. and/or other Patent Application and may not be used to infringe the patent claims.
Will protect against MDV and non-virus producing JM tumor transplant.
Biosafety Level 2

Biosafety  classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Isolation
chicken (S-strain) peripheral blood lymphocytes
Product Format frozen
Storage Conditions  Vapor phase of liquid nitrogen
Comments
Nononcogenic, cell associated. Will protect against MDV and non-virus producing JM tumor transplant. NOTE: This material is cited in a U.S. and/or other Patent Application and may not be used to infringe the patent claims.
Effect on Host
 CPE, cell rounding and syncytia formation
Recommended Host
chicken embryo fibroblasts
Growth Conditions
Temperature: 37°C
Incubation:  Incubate infected culture for 7 days at 37°C in a humidified 5% CO2 atmosphere, until CPE are well advance throughout.

Effect on Host
 CPE, cell rounding and syncytia formation
Name of Depositor BW Calnek
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished.
Source
chicken (S-strain) peripheral blood lymphocytes
References

Schat KA, Calnek BW. Characterization of an apparently nononcogenic Marek's disease. J. Natl. Cancer Inst. 60: 1075-1082, 1978. PubMed: 76680